Conv. Plasma
Nigella Sativa
Peg.. Lambda

All remdesivir studies
Meta analysis
Home COVID-19 treatment researchRemdesivirRemdesivir (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality -460% Improvement Relative Risk Remdesivir  Kurniyanto et al.  LATE TREATMENT Is late treatment with remdesivir beneficial for COVID-19? Retrospective 477 patients in Indonesia Higher mortality with remdesivir (p=0.00089) Kurniyanto et al., J. Clinical Virolog.., Feb 2022 Favors remdesivir Favors control

Factors Associated with Death and ICU Referral among COVID-19 Patients Hospitalized in the Secondary Referral Academic Hospital in East Jakarta, Indonesia

Kurniyanto et al., Journal of Clinical Virology Plus, doi:10.1016/j.jcvp.2022.100068
Feb 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 477 hospitalized patients in Indonesia, showing higher mortality with remdesivir in unadjusted results.
Gérard, Wu, Zhou show significantly increased risk of acute kidney injury with remdesivir. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details; substantial unadjusted confounding by indication likely.
This study includes favipiravir and remdesivir.
risk of death, 460.0% higher, RR 5.60, p < 0.001, treatment 7 of 45 (15.6%), control 12 of 432 (2.8%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kurniyanto et al., 28 Feb 2022, retrospective, Indonesia, peer-reviewed, 11 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperRemdesivirAll
Factors associated with death and ICU referral among COVID-19 patients hospitalized in the secondary referral academic hospital in East Jakarta, Indonesia
Kurniyanto, Yessi Setianegari, Linggom Kurniaty, Danny E J Luhulima, Bambang S R Utomo, Louisa A Langi, Ronny, Evy S Arodes, Marwito Wiyanto, Eva Suarthana, Retno Wahyuningsih
Journal of Clinical Virology Plus, doi:10.1016/j.jcvp.2022.100068
This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Authors contribution K is responsible for the patient during their hospitalization and writing the paper. RW design of the study, analyzed the data and writing the paper. ES analyzed the data, doing statistical analysis and writing the paper, All authors read and approved the final manuscript. Consent for publications Not applicable Competing interest The authors declare that they have no competing interest
Biswas, Rahaman, Biswas, Haque, Association of sex, age, and comorbidities with mortality in COVID-19 patients: A systematic review and meta-analysis, Intervirology, doi:10.1159/000512592
Chen, Liang, Jiang, Guan, Zhan et al., Risk factors of fatal outcome in hospitalized subjects with coronavirus disease 2019 from a nationwide analysis in China, Chest, doi:10.1016/j.chest.2020.04.010
Dong, Du, Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect Dis, doi:10.1016/S1473-3099(20)30120-1
Guan, Ni, Yu, Liang, Ou et al., Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032
Indonesia, Pedoman pencegahan dan pengendalian coronavirus disease (COVID-19) revisi ke-5
Jia, Yin, Lu, Chen, Liu et al., Two things about COVID-19 might need attention, Preprints, doi:10.20944/preprints202002.0315.v1
Li, Liu, Wu, Yi, Chen et al., D-Dimer as a prognostic indicator in critically ill patients hospitalized with COVID-19 in Leishenshan Hospital, Wuhan, China, Front Pharmacol, doi:10.3389/fphar.2020.600592
Peckham, De Gruijter, Raine, Radziszewska, Ciurtin et al., Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission, Nat Commun, doi:10.1038/s41467-020-19741-6
Peron, Nakaya, Susceptibility of the Elderly to SARS-CoV-2 Infection: ACE-2
Pouw, Van De Maat, Veerman, Oever, Janssen et al., Clinical characteristics and outcomes of 952 hospitalized COVID-19 patients in The Netherlands: A retrospective cohort study, PLoS One, doi:10.1371/journal.pone.0248713
Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area [published correction appears, JAMA
Suhendra, Elyazar, Djaafara, Ekawati, Saraswati et al., Clinical characteristics and mortality associated with COVID-19 in Jakarta, Indonesia: A hospital-based retrospective cohort study, Lancet Reg Health West Pac, doi:10.1016/j.lanwpc.2021.100108
Tamara, Tahapary, Obesity as a predictor for a poor prognosis of COVID-19: A systematic review, Diabetes Metab Syndr, doi:10.1016/j.dsx.2020.05.020
Zhang, Hu, Luo, Fang, Chen et al., Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China, J Clin Virol, doi:10.1016/j.jcv.2020.104364
Zhang, Wang, Jia, Li, Hu et al., Risk factors for disease severity, unimprovement, and mortality in COVID-19 patients in Wuhan, China, Clin Microbiol Infect, doi:10.1016/j.cmi.2020.04.012
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop